Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Masimo reports robust Q4 earnings, eyes new product launches

Masimo's Q4 2022 earnings call highlighted strong financial performance, growth projections for 2023, and a focus on innovation and regulatory advancements. While facing challenges like supply chain issues and legal disputes, the company remains optimistic about opportunities in new product launches and revenue growth drivers. Overall, Masimo is poised for continued success in the healthcare market.

Masimo reports robust Q1 earnings, navigates challenges with strategic focus

Masimo's Q1 performance reflects strong revenue growth and product innovation, underpinned by a focus on healthcare technology and wearables for chronic illness monitoring.
While facing challenges such as litigation costs and regulatory clearances, Masimo maintains its financial guidance for 2023, signaling stability and strategic resilience.
The company's emphasis on new product launches, diverse pricing strategies, and global market expansion positions it well to capitalize on opportunities in the healthcare sector.

Masimo faces revenue challenges in Q2 but eyes rebound

Masimo's Q2 performance was impacted by revenue challenges in Healthcare and non-healthcare segments, leading to a revised revenue guidance for 2023.
The company is focusing on expense control measures, new product opportunities, and pricing discipline to drive profitability and rebound in business segments.
Despite challenges, Masimo remains optimistic about market opportunities in telehealth, consumer health, and the potential for revenue growth from products like Stork.
Ongoing litigation with Apple and uncertainties in customer order patterns pose challenges, but the company is implementing strategies to address these issues.

Masimo reports solid Q3 earnings, eyes growth in consumer health

Masimo's Q3 performance showcased strong revenue but challenges in sensor utilization recovery. The company's innovative products and expansion into consumer health signal growth potential. Addressing challenges in revenue guidance and market competition will be key focus areas for future success.

Masimo reports robust Q4 earnings, legal wins and growth opportunities

Masimo's strong Q4 performance and strategic focus on healthcare and hearables/wearables growth position the company well for 2024.
Legal victories in Apple litigation and FDA clearances for innovative products underscore Masimo's commitment to innovation and protecting its intellectual property.
While facing challenges in legal proceedings and product clearances, Masimo has opportunities to drive revenue growth through product innovation and market expansion.

Masimo reports strong Q1 earnings, plans consumer business separation

Masimo's Q1 2024 Earnings Call showcased robust financial performance, strategic revenue diversification, and plans for enhancing shareholder value through potential separation of the consumer business. While facing challenges in operational transitions and financial metrics scrutiny, the company is well-positioned for growth and value creation.

Masimo reports robust Q3 performance and outlines growth opportunities

Masimo's Q3 2024 earnings call showcased strong financial performance, strategic reviews, and growth initiatives. While facing challenges in margin progression and potential disruptions, the company is poised for growth with opportunities in revenue expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Masimo is near a buy zone with earnings due on or around Oct. 27. The post Highly Rated Masimo Forms Later-Stage Base With Earnings Due appeared first on Investor's Business Daily.

Highly Rated Masimo Forms Later-Stage Base With Earnings Due

NEUCHATEL, Switzerland--(BUSINESS WIRE)--In an ASA abstract, researchers investigated whether Masimo ORi™ could predict the need for postoperative oxygen therapy in children with sleep apnea.

Researchers Use Masimo ORi™, Oxygen Reserve Index, to Predict the Need for Postoperative Oxygen Therapy in Pediatric Patients with Obstructive Sleep Apnea

Masimo's (MASI) wearable wireless continuous thermometer offers consumers hassle-free continuous body temperature measurements, thereby eliminating the need for manual measurements.

Masimo Unveils New Wearable Wireless Continuous Thermometer

Masimo, a maker medical devices that include a Covid-19 monitor, finally gave its first 2020 guidance and also posted preliminary third-quarter sales that beat expectation; MASI stock rose. The post Masimo Gives Its First 2020 Guidance After Covid-19 'Uncertainties'; MASI Stock Rises appeared first on Investor's Business Daily.

Masimo Gives Its First 2020 Guidance After Covid-19 'Uncertainties'; MASI Stock Rises

Columbia Sportswear Company

Edwards Lifesciences

Medifast

Mastech Digital

According to the All-in-One Screener, a Premium feature of GuruFocus, five stalwarts that have high financial strength and expanding operating margins include Mastech Digital Inc. (MHH), Columbia Sportswear Co. (NASDAQ:COLM), Medifast Inc. (NYSE:MED), Masimo Corp. (NASDAQ:MASI) and Edwards Lifesciences Corp. (NYSE:EW).

5 Peter Lynch Stalwarts With Expanding Profit Margins

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the third quarter ended September 26, 2020, and provided select financial estimates for its full-year 2020 guidance. Masimo expects its product revenue for the third quarter 2020 will range from $274 million to $278 million, which reflects reported growth of approximately 19.7% to 21.4% over the third quarter of 2019. The preliminary financial information presented in this

Masimo Announces Select Preliminary Third Quarter 2020 Financial Results and Updated Full-Year 2020 Guidance

IRVINE, Calif.--(BUSINESS WIRE)--Masimo is launching the wearable, wireless Radius Tº™ Continuous Thermometer for consumers.

Masimo Announces Consumer Launch of the Radius Tº™ Continuous Thermometer, a More Convenient Way to Keep Track of Fever

Apple

Copart

Exponent

New Historical Data Screen identifies stocks with high returns over the past 5 years

4 High-Quality Stocks With Strong Returns on Equity

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Rad-G™, which provides spot-checking and continuous monitoring with SET® pulse oximetry and other parameters, has received FDA clearance.

Masimo Announces FDA Clearance of the Rad-G™ Pulse Oximeter

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on Thursday, September 17, 2020 at 5:00 p.m.

Masimo to Present in Morgan Stanley 18th Annual Global Healthcare Conference

Modern Healthcare Honors Dr. Peter Pronovost as a Top 25 Innovator for Spearheading Remote Monitoring Program at University Hospitals Using Masimo’s Technology

Masimo's (MASI) O3 Regional Oximetry's FDA clearance can help clinicians offer quick and accurate care

Masimo's (MASI) O3 Regional Oximetry Attains FDA Approval

IRVINE, Calif.--(BUSINESS WIRE)--Masimo O3® Regional Oximetry is now additionally indicated for somatic applications and monitoring relative changes in cerebral hemoglobin.

Masimo O3® Regional Oximetry Receives FDA Clearance for Somatic Applications and Measurement of Relative Changes in Cerebral Hemoglobin

Masimo (MASI) reported earnings 30 days ago. What's next for the stock?

Masimo (MASI) Down 0.3% Since Last Earnings Report: Can It Rebound?

The pulse oximetry study result should be a major breakthrough for Masimo (MASI) to capture the neonatal patient care market.

Masimo Releases Favorable Study Results on Pulse Oximetry

NEUCHATEL, Switzerland--(BUSINESS WIRE)--Two new studies evaluated the use of Masimo SpHb®, noninvasive, continuous hemoglobin monitoring, on neonatal patients.

New Studies Investigate the Accuracy of Noninvasive, Continuous Hemoglobin Monitoring with Masimo SpHb® on Neonates

The FDA approval of Masimo's (MASI) PVi system will enable patient safety.

Masimo PVi Gets FDA Approval to Measure Fluid Responsiveness

IRVINE, Calif.--(BUSINESS WIRE)--Masimo PVi receives FDA clearance as a continuous, noninvasive, dynamic indicator of fluid responsiveness.

Masimo PVi® Receives FDA Clearance as an Indicator of Fluid Responsiveness on Mechanically Ventilated Patients

Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q2.

Masimo (MASI) Earnings and Revenues Beat Estimates in Q2

The company's noninvasive monitoring devices enjoyed especially strong demand for one overriding reason.

How Masimo Beat Expectations in Q2

Masimo's (MASI) CEO Joe Kiani on Q2 2020 Results - Earnings Call Transcript SA Transcripts

Masimo (MASI) delivered earnings and revenue surprises of 8.97% and 4.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) Surpasses Q2 Earnings and Revenue Estimates

DexCom

Medtech companies Masimo and Dexcom late Tuesday reported second-quarter earnings that beat expectations, but only Dexcom stock rose as Masimo declined to provide guidance for the year.
The post Dexcom Stock Up, Masimo Stock Slips On Medtech Earnings Beats appeared first on Investor's Business Daily.

Dexcom Stock Up, Masimo Stock Slips On Medtech Earnings Beats

Shares of Masimo (NASDAQ:MASI) decreased 2.25% in after-market trading after the company reported Q2 results.

Masimo: Q2 Earnings Insights

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (Nasdaq: MASI) today announced its financial results for the second quarter ended June 27, 2020.

News for Masimo Stock (MASI)